HQY Stock Analysis — HealthEquity
Sector: Healthcare
AI Verdict
HQY trades at 17.2x next year's earnings with nearly 2x EPS growth expected, making it cheap for the growth you're getting if its sticky HSA platform keeps delivering.
Competitive Moat
HealthEquity operates a scaled platform for health savings accounts (HSAs), integrating custodial services, payment processing, and benefits administration for employers and individuals. Its defensibility comes from regulatory complexity, sticky employer relationships, and a large base of managed assets that competitors struggle to dislodge.
Summary
HQY is notable for its sharp expected earnings rebound, with forward EPS growth forecast at 94.1%.
Where It Stands
Shares trade at 17.2x forward earnings, well below the healthcare sector median of 22x, while analysts expect EPS to nearly double next year.
Key Metrics
- Trailing P/E: 33.3x
- Forward P/E: 17.2x
- PEG Ratio: 0.35
- Earnings Growth: +0.9%
- Revenue Growth: +0.1%
- 52-Week High: $116.65
- 52-Week Low: $72.76
Analyst Consensus
18 Buy · 1 Hold · 1 Sell (20 analysts)
Bull Case
A 94.1% forward EPS growth rate against a 17.2x forward P/E means you're paying a low price for a potential earnings surge.
Bear Case
If the forward P/E reverts to the sector median of 22x after growth disappoints, the upside is capped, but if growth misses, a drop to 15x would mean a 13% valuation hit.
Catalyst to Watch
Watch for quarterly earnings — any sign that EPS growth is tracking below the 94.1% consensus could trigger a swift rerating.